Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa single-arm study of CVM-1118 plus sintilimab and TACE in unresectable non-metastatic hepatocellular carcinoma
CTR20261108Phase 2Active
- Sponsor
- TaiRx, Inc.
- Start
- Apr 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dasatinib and sintilimab in hepatocellular carcinoma (HCC), sponsored by TaiRx, Inc. Primary endpoint: Objective response rate. Started Apr 2026; status: active.
02
Drugs
dasatinibsintilimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20261108.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261108.